GRA VentureLab shines at SEBIO Investor Forum
GRA VentureLab was front and center at the 2010 SEBIO Investors Forum in Atlanta, November 3-5.
NRG Biotechnology, which became a GRA VentureLab project earlier this year, was the winner of Southeast BIO’s “BIO/Plan Competition.”
Built on technology developed in the laboratory of Dr. Byron Ford at Morehouse School of Medicine, NRG Biotechnology is exploring the therapeutic and market dimensions of a protein that has shown potential as a solution for the devastating inflammation associated with neurological attacks including stroke, traumatic brain injury and exposure to neurotoxins.
The competition, sponsored by Southeast BIO, is a year-long program to foster new, venture-attractive life sciences companies based in the Southeast. Three of the four finalists this year are GRA VentureLab investments. Joining NRG Biotechnology in the final four were Spectropath Medical and Reactive Diagnostics (RDI). Spectropath, part of GRA VentureLab at Emory University, is developing technology to visually assess the presence of malignant tissue; RDI, drawing on technology developed at Georgia Tech, is commercializing detection probes for use in research and clinical settings.
Also recognized were two VentureLab companies: InVasc, winner of the SEBIO Best Initial Financing Award, and NeurOp, which participated in the early stage company event. InVasc, spun out of Emory University, is developing drugs to reduce multiple risk factors of the cardiovascular system. NeurOp also got its start in the laboratories of Emory University; the company is developing medicines for the treatment of central nervous system disorders.
GRA VentureLab is the Georgia Research Alliance program that works with an array of research universities to commercialize promising technologies developed in their laboratories.
“We congratulate all of the companies presenting at the SEBIO Investor Forum,” said C. Michael Cassidy, president and CEO of the Georgia Research Alliance. “The range and potential of the lifesaving technologies these companies are developing is moving the Southeast to the forefront of the biotechnology industry.”